Page values for "Viloxazine"
From Pharmacopedia
More actions
"Medicines" values
1 row is stored for this page| Field | Field type | Value |
|---|---|---|
| generic | String | |
| brand | String | Qelbree |
| structure | File | |
| classes | List of String, delimiter: , | Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism • non-stimulant ADHD agent |
| mechanism | String | Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. |
| uses | String | ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) |
| starting_dose | String | Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. |
| preparations | String | 100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) |
| fda_max | String | 400 mg/d (pediatric); 600 mg/d (adult) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) |
| duration | String | Daily dosing |
| halflife | String | ~7 hours |
| bioavailability | String | Adequate oral bioavailability with extended-release formulation |
| pregnancy | String | Limited data |
| legal | String | Rx, '''not a controlled substance''' (no DEA scheduling) |